Table 1 Baseline characteristics and treatment modalities
Characteristics | Total (n = 98) |
|---|---|
Demographics: | |
Male | 70 (71) |
Age at treatment start (yr.) | 62 [24–82] |
IMDC score at treatment start (n = 80) | |
Favourable risk | 19 (24) |
Intermediate risk | 40 (50) |
Poor risk | 21 (26) |
Medical history: | |
Hypertension (n = 73) | 14 (19) |
Tobacco use (n = 86) | |
Active | 19 (22) |
Ceased | 24 (28) |
None | 43 (50) |
Tumour characteristics: | |
Histology | |
Clear cell | 85 (87) |
Othera | 13 (13) |
Fuhrman grade (n = 79) | |
I-II | 23 (29) |
III | 40 (51) |
IV | 16 (20) |
TNM staging (n = 80) | |
T1 | 15 (19) |
T2 | 21 (26) |
T3–4 | 44 (55) |
M1 at initial diagnosis | 36 (45) |
Pulmonary metastasis (n = 98) | 77 (78) |
Treatment: | |
Prior nephrectomy | 86 (88) |
Number of lines of treatment at axitinib start | 3 [2–7] |
Treatment duration (mo.) | 8 [3–30] |
Causes of axitinib discontinuation (n = 83) | |
Progression | 57 (68.5) |
Toxicity | 13 (15.5) |
Death | 9 (11) |
Other | 4 (5) |
Biology at axitinib start: | |
Haemoglobin serum level (g/dL) (n = 98) | 12.5 [8.4–16.8] |
Creatinine serum level (μmol/L) (n = 78) | 101.5 [39–215] |
Chronic kidney disease (n = 78) | |
Grade 1 | 41 (52) |
Grade 2 | 36 (46) |
Grade 3 | 1 (1) |